Mednax (MD) Reports In-Line Q2 EPS; Comps Up 1.8%; Guides Lighter Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MD Hot Sheet
Join SI Premium – FREE
Mednax (NYSE: MD) reported Q2 EPS of $1.15, in-line with the analyst estimate of $1.15. Revenue for the quarter came in at $393.4 million versus the consensus estimate of $394.57 million.
Same-unit revenue growth from reimbursement-related factors was 1.8 percent.
Mednax sees Q3 2011 EPS of $1.15-$1.20, versus the consensus of $1.20.
Same-unit revenue growth from reimbursement-related factors was 1.8 percent.
Mednax sees Q3 2011 EPS of $1.15-$1.20, versus the consensus of $1.20.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- First Citizens Bancshares (FCNCA) reported Q3 EPS
- Rogers Communications (RCI) Tops Q3 EPS by 42c
Create E-mail Alert Related Categories
Earnings, Guidance, Retail SalesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
